RDHL - RedHill Biopharma Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.00
-0.07 (-1.15%)
At close: 4:00PM EDT

5.88 -0.12 (-2.00%)
After hours: 4:29PM EDT

Stock chart is not supported by your current browser
Previous Close6.07
Open6.05
Bid5.00 x 800
Ask6.00 x 800
Day's Range5.60 - 6.16
52 Week Range4.30 - 11.49
Volume358,396
Avg. Volume256,940
Market Cap156.752M
Beta1.53
PE Ratio (TTM)N/A
EPS (TTM)-2.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.17
Trade prices are not sourced from all markets
  • Raleigh's RedHill Biopharma is $25 million richer
    American City Business Journals7 hours ago

    Raleigh's RedHill Biopharma is $25 million richer

    Executives at RedHill Biopharma (Nasdaq: RDHL) knew that to forward the company's drug development process, it needed to raise money — fast.

  • GlobeNewswire11 hours ago

    RedHill Biopharma Announces Closing of $25 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the closing of its previously announced underwritten offering of 4,166,667 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at an offering price of $6.00 per ADS, for gross proceeds of approximately $25 million, before commissions and other offering expenses. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund clinical development programs, including preparations for a second Phase III study with RHB-104 for Crohn’s disease, initiation of a pivotal Phase III study with RHB-204 for NTM, for commercial operations including TALICIA® (H. pylori) launch preparations, acquisitions, and general corporate purposes.

  • GlobeNewswire2 days ago

    RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new formulation patent, expected to be valid until at least 2029, that further expands the Company’s intellectual property portfolio covering RHB-104 for Crohn’s disease and RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections. Danielle Abramson, Ph.D., RedHill’s Vice President, Intellectual Property & Research, said: “RedHill has a robust patent portfolio covering the proprietary formulation of RHB-104 and its use in treating Crohn’s disease, including several issued U.S. patents.

  • GlobeNewswire5 days ago

    RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the pricing of an underwritten offering of 4,166,667 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at an offering price of $6.00 per ADS, for gross proceeds of approximately $25 million, before commissions and other offering expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American:LTS), is acting as the sole book-running manager for the offering. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund clinical development programs, including preparations for a second Phase III study with RHB-104 for Crohn’s disease, initiation of a pivotal Phase III study with RHB-204 for NTM, for commercial operations including TALICIA® (H. pylori) launch preparations, acquisitions, and general corporate purposes.

  • Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
    Zacks12 days ago

    Medical-Drugs Stock Outlook: No Respite from Near-Term Pain

    Medical-Drugs Stock Outlook: No Respite from Near-Term Pain

  • GlobeNewswire14 days ago

    RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today elaborated on the previously announced positive top-line results from the first Phase III study with orally-administered RHB-104 for Crohn’s disease (the MAP US study). “Based on the feedback from our shareholders, stakeholders and other market participants, we believe certain aspects of our MAP US Phase III study top-line results may not have been sufficiently clear, particularly in relation to the secondary endpoint of standalone week 52 remission. The Company reiterates that its MAP US first Phase III study with RHB-104 successfully met its primary endpoint, as well as key secondary endpoints, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104.

  • Why Redhill Biopharma Ltd. Stock Is Soaring Today
    Motley Fool15 days ago

    Why Redhill Biopharma Ltd. Stock Is Soaring Today

    Redhill's late-stage Crohn's disease drug hits the mark in a late-stage trial.

  • Benzinga15 days ago

    RedHill Earns Long-Awaited Boost On Positive Crohn's Data

    REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release . What Happened The drug met both primary ...

  • Reuters16 days ago

    RedHill BioPharma has positive results from Crohn's disease trial

    Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104. The study met its primary endpoint and key secondary endpoints, demonstrating the drug's superiority over a placebo in achieving remission of the gastrointestinal disease at week 26, the company said in a statement. "The proportion of patients meeting the primary endpoint was significantly greater in the RHB-104 group compared to placebo," RedHill said.

  • GlobeNewswire16 days ago

    RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today announced positive top-line safety and efficacy results from the first Phase III study with RHB-104 for Crohn’s disease (the MAP US study). The study successfully met its primary endpoint and key secondary endpoints.

  • GlobeNewswire21 days ago

    RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi®

    Mytesi ® is an FDA-approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy Mytesi ® is the fourth product ...

  • GlobeNewswire22 days ago

    RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    TEL-AVIV, Israel and RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that it has enrolled 400 of the planned total of 444 patients in the ongoing confirmatory Phase III study investigating TALICIA® (RHB-105)1 for H. pylori infection (ERADICATE Hp2). “RedHill is on track to complete enrollment of the ERADICATE Hp2 study in the coming weeks, and we expect to announce top-line results in the fourth quarter of this year,” said Dror Ben-Asher, RedHill’s Chief Executive Officer.

  • GlobeNewswire23 days ago

    RedHill Biopharma Announces Uplisting to Nasdaq Global Market

    TEL-AVIV, Israel and RALEIGH, N.C., July 23, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that Nasdaq Stock Market LLC has approved the uplisting of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Market. The ADSs were previously traded on the Nasdaq Capital Market.

  • RedHill Gets Two New Patents for Crohn's Disease Candidate
    Zackslast month

    RedHill Gets Two New Patents for Crohn's Disease Candidate

    RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.

  • RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
    Zackslast month

    RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%

    RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswirelast month

    RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., July 02, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal (GI) diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) and an Intention to Grant from the European Patent Office (EPO) for two new patents covering RHB-104, expected to be valid until at least February 5, 2029, once granted. The development of RHB-104 for Crohn’s disease is based on the hypothesis that Crohn’s disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients.

  • ACCESSWIRE2 months ago

    Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product

    SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), today announced that it has entered into an agreement (the Agreement) with RedHill Biopharma Ltd. (RedHill) (RDHL), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, to establish a U.S. co-promotion program for Mytesi® (crofelemer 125 mg delayed-release tablets), Napo's FDA-approved drug, for the current approved indication. Mytesi is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®

    RedHill has been granted the exclusive right to co-promote Mytesi ® in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by ...

  • RedHill Biopharma (RDHL): Moving Average Crossover Alert
    Zacks2 months ago

    RedHill Biopharma (RDHL): Moving Average Crossover Alert

    RedHill Biopharma Ltd. (RDHL) is looking like an interesting pick from a technical perspective

  • RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?
    Zacks2 months ago

    RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in RedHill Biopharma Ltd. (RDHL)

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BiondVax ...

  • Is RedHill's experimental Ebola treatment on FDA fast track?
    American City Business Journals2 months ago

    Is RedHill's experimental Ebola treatment on FDA fast track?

    With a new patent in hand, Tel-Aviv-based RedHill Biopharma – which is growing its U.S. commercial operations from Raleigh – is looking to advance an experimental treatment for Ebola virus.  RedHill (Nasdaq: RDHL) said Tuesday that the United States Patent and Trademark Office has issued a patent covering the experimental treatment until 2035.  RedHill has completed a proof-of-concept study looking at survival outcomes and disease severity through a research collaboration with the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. When it comes to other pharmaceutical companies working in the space, most are focused on developing a vaccine for people at risk of contracting Ebola.

  • GlobeNewswire3 months ago

    RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018

    TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018-- RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...

  • GlobeNewswire3 months ago

    RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy

    TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering RedHill’s proprietary experimental therapy for the treatment of Ebola virus disease. As part of RedHill’s research collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), the Company successfully completed a proof-of-concept study to evaluate its proprietary experimental therapy for the treatment of Ebola virus disease.